Final analysis of Panorama 1: Phase 3 trial of panobinostat for multiple myeloma

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Sagar Lonial, MD, from Emory University Winship Cancer Institute, Atlanta, GA, discusses the final analysis of overall survival from Panorama 1, a phase 3 clinical trial that evaluated panobinostat, a histone deacetylase inhibitor, plus bortezomib, a proteasome inhibitor, and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma.